OXFORD, U.K: Sensyne Health plc has signed a five year non-exclusive Strategic Research Agreement (SRA) with Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH) to analyse anonymised patient data using clinical artificial intelligence (Clinical AI) technology. The purpose of the SRA is to enable the ethical application of Clinical AI research to…
DELAWARE: Sensyne Health plc (LON: SENS) has signed its first Strategic Research Agreement (SRA) in the United States of America with St. Luke’s University Health Network, a leading U.S. health system serving patients in Pennsylvania and New Jersey. The agreement will enable the ethical application of clinical AI research to improve patient care and…
OXFORD: Sensyne Health plc has signed a five year non-exclusive Strategic Research Agreement (SRA) with The Royal Wolverhampton NHS Trust. The agreement will enable the ethical application of clinical AI research to improve patient care and accelerate research into new medicines. The RWT dataset covers 700,000 unique patient records from a patient population of…
OXFORD: Sensyne Health plc has launched GDm-Health, its remote monitoring solution for diabetes in pregnancy, in the U.S. with immediate effect. Sensyne’s sales and marketing partner for the U.S., Cognizant, is now offering the solution to U.S. health systems and health plans via its sales force. Virtual care services powered by GDm-Health will qualify…
OXFORD: Sensyne Health plc has signed a five year non-exclusive Strategic Research Agreement (SRA) with Somerset NHS Foundation Trust, a news release said. The agreement will enable the ethical application of clinical AI research to improve patient care and accelerate research into new medicines. The Somerset dataset covers 1.1 million unique patient records from…
OXFORD: Sensyne Health plc, the UK Clinical AI company, has signed a research collaboration agreement with Bristol Myers Squibb (BMS). Initially the collaboration will focus on applying Sensyne’s proprietary machine learning to conduct research into disease progression and patient stratification for patients with various diseases within the broader group of Myeloproliferative Neoplasms (MPNs). MPNs…
OXFORD, UK: Sensyne Health plc, the British clinical AI technology company, has joined Bayer’s LifeHub UK in an extension of its existing collaboration with Bayer to accelerate the development of new treatments using clinical artificial intelligence. Sensyne Health will work in partnership with Bayer on novel projects at the LifeHub UK including its inaugural…